SecBot SecBot
PRESS-RELEASE ·Filed May 6, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should expect upward price pressure as the market digests the positive clinical validation. Monitor for regulatory submission milestones and potential partnership or M&A interest given the high unmet need.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$142.51
T+0 close · May 6, 2026 · via day close
Latest settled
+28.03%
T+60 · $182.45
Vs SPY
+24.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $142.51entry
  2. T+1 · 6mo ago 0.00%α −0.83% · $142.51
  3. T+5 · 6mo ago +5.21%α +3.71% · $149.94
  4. T+20 · 6mo ago +9.46%α +6.32% · $155.99
  5. T+60 · 4mo ago +28.03%α +24.19% · $182.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NEJM, complementing recently reported positive Phase 3 topline results showing an unprecedented overall survival benefit. The drug holds FDA Breakthrough Therapy and Orphan Drug Designations, reinforcing its potential as a new standard of care for a deadly cancer with limited treatment options.

Key Facts

  • NEJM published Phase 1/2 data for daraxonrasib in metastatic RAS-mutant PDAC.
  • Company previously announced positive Phase 3 RASolute 302 topline results with unprecedented overall survival benefit vs. standard chemotherapy.
  • Daraxonrasib has FDA Breakthrough Therapy and Orphan Drug Designations for PDAC with G12 mutations.
  • Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting diverse RAS mutations.
  • Three additional global Phase 3 registrational trials are ongoing, including earlier-line PDAC and NSCLC.

Financial Impact

Positive clinical data significantly increases probability of regulatory approval and peak sales potential, estimated by analysts in the multi-billion dollar range for PDAC indication alone.

probability of approvalpeak revenue estimatesvaluation multiples

Risk Factors

  • Regulatory approval not guaranteed; pivotal trial results may not replicate in larger populations.
  • Competition from other RAS inhibitors (e.g., from Mirati, Amgen) could limit market share.
  • Risk of toxicity or safety issues in ongoing broader clinical development.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289496

US Market Status

Market Closed · Opens Wed (10h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026